` RGNX (Regenxbio Inc) vs S&P 500 Comparison - Alpha Spread

RGNX
vs
S&P 500

Over the past 12 months, RGNX has underperformed S&P 500, delivering a return of -29% compared to the S&P 500's 9% growth.

Stocks Performance
RGNX vs S&P 500

Loading
RGNX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RGNX vs S&P 500

Performance Gap Between RGNX and GSPC
HIDDEN
Show

Performance By Year
RGNX vs S&P 500

Loading
RGNX
S&P 500
Add Stock

Competitors Performance
Regenxbio Inc vs Peers

S&P 500
RGNX
ABBV
AMGN
GILD
VRTX
Add Stock

Regenxbio Inc
Glance View

Market Cap
429.5m USD
Industry
Biotechnology

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 372 full-time employees. The company went IPO on 2015-09-17. The Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates use adeno-associated virus (AAV) vectors from its gene delivery platform, called NAV Technology Platform. Its product candidate includes RGX-314, RGX-111, RGX-121, RGX-202, RGX 181 and RGX-381. RGX-314 is meant for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) and other anti-VEGF treated conditions. The company is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II). RGX-202 is its product candidate for the treatment of duchenne muscular dystrophy (DMD).

RGNX Intrinsic Value
HIDDEN
Show
Back to Top